Navigation Links
Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models

- Data presentations at American Association for Cancer Research annual meeting -

PRINCETON, N.J., April 17, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. today presented preclinical data demonstrating potent anti- tumor activity from two separate studies exploring the efficacy and safety in animal models of anti-CD19 and anti-CD70 antibody-drug conjugates. CD19 and CD70 are both attractive targets for an antibody-drug conjugate approach to cancer therapy. They are expressed on cancer cells with limited normal patterns of expression and are rapidly internalized when bound to antibody. Data from the studies were presented at the American Association for Cancer Research (AACR) annual meeting, April 14-18, 2007, in Los Angeles, CA.

Efficacy study of anti-CD19 antibody drug conjugates in Raji tumor xenograft and systemic model (Abstract #4104)

CD19 is expressed on B cell cancers, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and acute lymphocytic leukemia. Single dose treatments of a fully human anti-CD19 antibody drug conjugate demonstrated in vivo anti-tumor efficacy leading to the regression of established subcutaneous tumors and systemic tumors in leukemia xenograft models. Anti-CD19 antibody- drug conjugate was well-tolerated and without toxicity in the animal models.

Single, low dose treatment of lymphoma and renal cancer xenografts with human anti-CD70 antibody toxin conjugates, results in long term cures (Abstract #4112)

CD70 is highly expressed in multiple tumor types, including many lymphomas and clear cell renal cancer. Single, low dose treatments of a fully human anti-CD70 antibody drug conjugate demonstrated in vivo anti-tumor efficacy in both preclinical lymphoma and renal cancer xenograft animal models. The anti- CD70 antibody drug conjugate demonstrated a high specificity for its target, a wide therapeutic window of activity, and a favorable toxicity and s afety profiles in larger animals at dose levels which are in excess of an efficacious dose determined in the xenograft models.

"Antibody-drug conjugates exploit the specificity of antibodies and the potency of cytotoxic agents to destroy cancer cells," said Nils Lonberg, PhD, Senior Vice President and Science Director at Medarex. "We believe that the anti-tumor activity from these preclinical antibody-drug conjugate studies is quite compelling, and we look forward to fully exploring the safety and therapeutic activity and application of these programs in future clinical trials."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with six of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements exp ressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, risks that favorable efficacy and safety results in animal models will not be replicated in humans, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


     Laura S. Choi                   Jean Mantuano

     Investor Relations              Corporate Communications (media)

Phone: 609-430-2880, x2216, Phone: 609-430-2880, x2221

CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, ext. 2216, orJean Mantuano, Corporate Communications (media), +1-609-430-2880, ext.2221, both of Medarex, Inc.

Web site: http://www.medarex.com/

Company News On-Call: http://www.prnewswire.com/comp/108265.html/

T icker Symbol: (NASDAQ-NMS:MEDX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... James Gilbart , ... 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... recently in a supplement to European Oncology & ... article by James Gilbart and ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
(Date:1/19/2017)... PALO ALTO, Calif. , Jan. 19, 2017 /PRNewswire/ ... scientific research, is excited to announce that the ... Project: Cancer Biology  (RP:CB) have been published in ... science, this project represents the first practical evaluation ... that result in reproducible studies. Unlike other assessments ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest ... for each of his children. “The Angel” is the creation of published author, Marjorie ... York City, and impassioned writer. , When asked of her new book, Marjorie says, ...
(Date:1/20/2017)... ... ... fine examination of how God handles sin, including how to let go of lingering guilt ... over ten long years has been waiting to release this powerful insight about forgiveness that ... serving the Lord for over twenty years, and he has been preaching and teaching the ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Christmas in ... creation of published author, Sara Seymour, who lives in Lafayette, Indiana where she works ... sips on iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s ...
Breaking Medicine News(10 mins):